The emergence of drugs like copyright and Semaglutide signifies a significant shift in how we manage metabolic disorders. These new therapies belong to a class known as GLP-1 receptor agonists, which replicate the effects of a natural hormone that regulates sugar levels and food intake. Initially, developed for diabetic conditions, their effectiven